Close Menu

NEW YORK – The European Commission has approved gilteritinib (Astellas' Xospata) as a treatment for adult acute myeloid leukemia who have relapsed or refractory disease characterized by FLT3 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.